3 citations
,
January 2025 in “Scientific Reports” This study found that treating asymptomatic or mild COVID-19 with cepharanthine did not significantly reduce the time to a negative test result, though 60 mg/day showed a non-significant trend needing further validation.
1 citations
,
January 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” In this study, 60 mg/day of Cepharanthine significantly reduced the time to a negative COVID-19 test among de novo infected patients with good compliance, though 120 mg/day showed no such effect.
36 citations
,
October 2002 in “The Journal of Dermatology” This study suggests that combining topical squaric acid dibutylester with other therapies may improve hair regrowth in patients with alopecia areata unresponsive to topical therapy alone.
70 citations
,
July 2020 in “Pharmacological Reports” This review discusses the antiviral potential of cepharanthine against SARS-CoV-2, noting its effectiveness in preclinical models but presenting no new clinical results.
14 citations
,
April 2022 in “Molecules” This study found that pulmonary delivery of cepharanthine significantly improved bioavailability and may provide protective effects against pulmonary fibrosis related to COVID-19 infection in a rat model.